1 50% or greater reduction in seizure frequency |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.97, 1.31] |
2 75% or greater reduction in seizure frequency |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.52 [1.12, 2.05] |
3 25% or greater reduction in seizure frequency |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.93, 1.11] |
4 75% or greater reduction in seizure duration |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.9 [0.97, 3.74] |
5 50% or greater reduction in seizure duration |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [1.03, 1.62] |
6 4 points or greater improvement in EEG |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
7 2 points or greater improvement in EEG |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
8 Post‐treatment EEG abnormality |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
8.1 Any abnormality |
2 |
120 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.79 [0.59, 1.04] |
8.2 Severe abnormality |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.87] |
8.3 Moderate abnormality |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.21, 2.13] |
8.4 Mild abnormality |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.40, 1.68] |
8.5 Borderline abnormality |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.33, 5.45] |